Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chad Peterson

MOHS-Micrographic Surgery Spanish Fork, UT Doctor of Osteopathy

NPI 1821299751 CMS profile 264878

114 E 800 N, Spanish Fork, UT 84660

Open in the dashboard

General payments

$6,403

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,632 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Chad Peterson of Spanish Fork, UT is reported in the CMS Open Payments database as having received $6,403 across 339 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,632 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $841 44
2024 General $930 48
2023 General $748 35
2022 General $721 32
2021 General $1,048 62
2020 General $853 44
2019 General $1,262 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chad Peterson
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Chad Peterson were reported at $841. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Chad Peterson MOHS-Micrographic Surgery median Middle half National median
2019 $1,262 $316 $106–$785 $163
2020 $853 $162 $68–$412 $114
2021 $1,048 $243 $87–$654 $132
2022 $721 $300 $102–$887 $149
2023 $748 $364 $125–$1,010 $160
2024 $930 $445 $142–$1,108 $164
2025 $841 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $902 62 payments
  2. Janssen Biotech, Inc. $655 36 payments
  3. Sun Pharmaceutical Industries Inc. $621 38 payments
  4. UCB, Inc. $580 22 payments
  5. Pfizer Inc. $565 36 payments
  6. Novartis Pharmaceuticals Corporation $492 28 payments
  7. Lilly USA, LLC $448 23 payments
  8. PruGen, Inc. Pharmaceuticals $323 4 payments
  9. Genzyme Corporation $302 15 payments
  10. LEO Pharma Inc. $212 10 payments
  11. Other $1,302 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,104 336 payments
  2. Education $299 3 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $646 46 payments
  2. TREMFYA $641 35 payments
  3. HUMIRA $483 36 payments
  4. ILUMYA $453 29 payments
  5. TALTZ $448 23 payments
  6. Cimzia $420 16 payments
  7. LITFULO $313 19 payments
  8. DUPIXENT $284 11 payments
  9. ADBRY $212 10 payments
  10. VTAMA $175 8 payments
  11. Other $2,594 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

526

Median for Dermatology: 534

Drug cost

$10,036

Median for Dermatology: $67,151

Branded share of claims

3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Betamethasone Dipropionate Generic 63 $2,412
Fluorouracil Generic 26 $1,711
Clobetasol Propionate Generic 24 $1,211
Cephalexin Generic 201 $971
Minocycline Hcl Generic 36 $962
Triamcinolone Acetonide Generic 59 $760
Doxycycline Hyclate Generic 15 $704
Methotrexate Methotrexate Sodium Brand 16 $455
Doxycycline Monohydrate Generic 15 $261
Terbinafine Hcl Generic 20 $217

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$350,162

Of which drugs: $1,479

Medicare patients

509

Average age 76

Services billed

4,083

245 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Diabetes 32%
Chronic kidney disease 25%
Ischemic heart disease 21%
Depression 21%
Atrial fibrillation 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 22 146 $704
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 194 $136

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $215
$215 — —
LITFULO
  • PFIZER INC. $98
$98 — —
ADBRY
  • LEO Pharma Inc. $95
$95 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $82
$82 — —
VTAMA
  • Dermavant Sciences, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record